Intraurethral alprostadil for erectile dysfunction: A review of the literature

Drugs

Volumn 72, Issue 17, 2012, Pages 2243-2254

  Costa, Pierre ^a   Potempa, Axel Juerg ^b  

^a DEPARTMENT OF NEUROLOGY   (France)

^b Center of Excellence for Urology Andrology Sexual and Partnership Medicine   (Germany)

Author keywords

Alprostadil; Erectile dysfunction; Erectile dysfunction Therapies; Intracavernosal; Prazosin; Sildenafil; Type 5 cyclic nucleotide phosphodiesterase inhibitors; Urethral.

Indexed keywords

ANOREXIGENIC AGENT; ANTIHYPERTENSIVE AGENT; CYCLIC AMP; DECONGESTIVE AGENT; MACROGOL; PHOSPHODIESTERASE V INHIBITOR; PRAZOSIN; PROSTAGLANDIN E1; PROSTAVASIN; SILDENAFIL;

BURN; DIZZINESS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PELLET; DRUG SAFETY; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; EUROPE; FAINTNESS; FLUSHING; GOLD STANDARD; HEADACHE; HUMAN; HYPOTENSION; INTERNATIONAL INDEX OF ERECTILE FUNCTION; MALE; MEDICATED SYSTEM FOR ERECTION; MONOTHERAPY; PAIN; PATIENT COMPLIANCE; PATIENT PREFERENCE; PENILE FIBROSIS; PENILE PAIN; PREVALENCE; PRIAPISM; PROSTATECTOMY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SCROTAL PAIN; SEXUAL INTERCOURSE; SEXUAL SATISFACTION; SIDE EFFECT; URETHRAL BLEEDING; URETHRAL PAIN; VASODILATATION;

ALPROSTADIL; DRUG ADMINISTRATION ROUTES; ERECTILE DYSFUNCTION; HUMANS; MALE; PENILE ERECTION; PIPERAZINES; PURINES; SULFONES; TREATMENT OUTCOME; URETHRA; VASODILATOR AGENTS;

EID: 84870030342     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11641380-000000000-00000     Document Type: Review

References (47)

1. Lue TF, Giuliano F, Montorsi F, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004; 1 (1): 6-23
2. Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 2000; 12 (6): 305-11
3. Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I, et al. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol 2001; 166 (2): 569-74
4. Rosen RC, Fisher WA, Eardley I, et al. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004; 20 (5): 607-17
5. Corona G, Lee DM, Forti G, et al. Age-related changes in general and sexual health in middle-Aged and older men: results from the European Male Ageing Study (EMAS). J Sex Med 2010; 7: 1362-80
6. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84 (1): 50-6
7. Bacon CG, Mittleman MA, Kawachi I, et al. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Int Med 2003; 139: 161-8
8. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61
9. American Urological Association. Management of erectile dysfunction ('05/updated '06) [online]. Available from URL: http://www.auanet.org/content/ guidelines-And-quality-care/clinical-guidelines.cfm?sub=ed [Accessed 2012 Nov 7]
10. Hackett G, Kell P, Ralph D, et al. British society for sexual medicine guidelines on the management of erectile dysfunction. J Sex Med 2008 Aug; 5 (8): 1841-65
11. Heidelbaugh JJ. Management of erectile dysfunction. Am Fam Physician 2010 01 Feb; 81 (3): 305-12
12. Morley JE, Kaiser FE. Impotence: the internist's approach to diagnosis and treatment. Adv InternMed 1993; 38: 151-68
13. Schouten BWV, Bohnen AM, Bosch JLHR, et al. Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen Study. Int J Impot Res 2008; 20 (1): 92-9
14. Nandipati KC, Raina R, Agarwal A, et al. Erectile dysfunction following radical retropubic prostatectomy: epidemiology, pathophysiology and pharmacological management. Drugs Aging 2006; 23 (2): 101-17
15. Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010; 57: 804-14
16. Derogatis LR, Meyer JK. A psychological profile of the sexual dysfunctions. Arch Sex Behav 1979; 8 (3): 201-23
17. Helgason AR, Adolfsson J, Dickman P, et al. Sexual desire, erection, orgasm and ejaculatory functions and their importance to elderly Swedish men: a population-based study. Age Ageing 1996; 25 (4): 285-91
18. Jeong JY, Lee SK, Kang YW, et al. Relationship between ED and depression among middle-Aged and elderly men in Korea: Hallym aging study. International J Impot Res 2011; 23 (5): 227-34
19. Donnelly DA. Sexually inactive marriages. J Sex Res 1993; 30: 171-9
20. Litzinger S, Gordon KC. Exploring relationships among communication, sexual satisfaction, and marital satisfaction. J Sex Marital Ther 2005 Oct-Dec; 31 (5): 409-24
21. Wespes E, Amar E, Hatzichristou D, et al. Guidelines on erectile dysfunction. Eur Urol 2002; 41 (1): 1-5
22. Montague DK, Jarow JP, Broderick GA, et al. Chapter 1: the management of erectile dysfunction: an AUA update. J Urol 2005 Jul; 174 (1): 230-9
23. Gupta R, Kirschen J, Barrow RC, et al. Predictors of success and risk factors for attrition in the use of intracavernous injection. J Urol 1997; 157 (5): 1681-6
24. Irwin MB, Kata EJ. High attrition rate with intracavernous injection of prostaglandin E1 for impotency. Urology 1994; 43 (1): 84-7
25. Weiss JN, Badlani GH, Ravalli R, et al. Reasons for high drop-out rate with self-injection therapy for impotence. Int J Impot Res 1994; 6 (3): 171-4
26. Linet OT, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 1996; 334 (14): 873-7
27. Nehra A. Oral and non-oral combination therapy for erectile dysfunction. Rev Urol 2007; 9 (3): 99-105
28. MEDA Pharmaceuticals Ltd. MUSE (alprostadil) 1000 microgram urethral stick. Summary of product characteristics. 2009 Aug 1 [online]. Available from URL: http://www. medicines.org.uk/EMC/medicine/22218/SPC/MUSE+1000+ microgram+urethral+stick [Accessed 2011 Dec 18]
29. MEDA. Evaluation of the relevant pharmacokinetics of alprostadil (PGE1) administered by MUSE. Clinical expert report study 94-06. Clinical Pharmacology. Data on file
30. MEDA Pharmaceuticals Inc. MUSE-(alprostadil) urethral suppository: prescribing information. 2011 Feb [online]. Available from URL: http://www.muserx.net/res/pack-inserts-PFI-1.3.pdf [Accessed 2011 Dec 18]
31. Padma-Nathan H, HellstromWJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 1997 Jan 2; 336 (1): 1-7
32. Ekman P, Sjogren L, Englund G, et al. Optimizing the therapeutic approach of transurethral alprostadil. BJU Int 2000 Jul; 86 (1): 68-74
33. Hellstrom WJ, Bennett AH, Gesundheit N, et al. A doubleblind, placebo-controlled evaluation of the erectile response to transurethral alprostadil. Urology 1996 Dec; 48 (6): 851-6
34. Williams G, Abbou CC, Amar ET, et al. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group. Br J Urol 1998 Jun; 81 (6): 889-94
35. McCullough AR, Hellstrom WG, Wang R, et al. Recovery of erectile function after nerve sparing radical prostatectomy and penile rehabilitation with nightly intraurethral alprostadil versus sildenafil citrate. J Urol 2010 Jun; 183 (6): 2451-6
36. Porst H. Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil: a comparative study in 103 patients with erectile dysfunction. Int J Impot Res 1997 Dec; 9 (4): 187-92
37. Shabsigh R, Padma-Nathan H, Gittleman M, et al. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study. Urology 2000 Jan; 55 (1): 109-13
38. Shokeir AA, Alserafi MA, Mutabagani H. Intracavernosal versus intraurethral alprostadil: a prospective randomized study. BJU Int 1999 May; 83 (7): 812-5
39. Peterson CA, Bennett AH, Hellstrom WJG, et al. Erectile response to transurethral alprostadil, prazosin and alprostadil-prazosin combinations. J Urol 1998 May; 159 (5): 1523-8
40. Potempa AJ, Potempa DM, Gorlich HD, et al. Intraurethrally applicated alprostadil for the treatment of organic erectile dysfunction in practice: a multicenter clinical monitoring study (noninterventional investigation) [in German]. Arzl Forsch 2007; 57 (6): 299-308
41. Williams G, Abbou CC, Amar ET, et al. The effect of transurethral alprostadil on the quality of life of men with erectile dysfunction, and their partners. MUSE Study Group. Br J Urol 1998 Dec; 82 (6): 847-54
42. Werthman P, Rajfer J. MUSE therapy: preliminary clinical observations. Urology 1997; 50 (5): 809-11
43. Mydlo JH, Volpe MA, MacChia RJ. Results from different patient populations using combined therapy with alprostadil and sildenafil: predictors of satisfaction. BJU Int 2000 Sep; 86 (4): 469-73
44. Mydlo JH, Volpe MA, Macchia RJ. Initial results utilizing combination therapy for patients with a suboptimal response to either alprostadil or sildenafil monotherapy. Eur Urol 2000 Jul; 38 (1): 30-4
45. Nehra A, Blute ML, Barrett DM, et al. Rationale for combination therapy of intraurethral prostaglandin E(1) and sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapy. Int J Impot Res 2002 Feb; 14 Suppl. 1: S38-42
46. Raina R, Nandipati KC, Agarwal A, et al. Combination therapy: medicated urethral system for erection enhances sexual satisfaction in sildenafil citrate failure following nerve-sparing radical prostatectomy. J Androl 2005; 26 (6): 757-60
47. Raina R, Agarwal A, Zaramo CE, et al. Long-term efficacy and compliance of MUSE for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis. Int J Impot Res 2005 Jan-Feb; 17 (1): 86-90